Federal contract award
75N94022F00001
THE GOAL OF THIS TASK ORDER IS TO PERFORM PHARMACOEPIDEMIOLOGY RESEARCH AND A PK, PHARMACODYNAMIC, PHARMACOGENOMIC, EFFICIENCY, AND SAFETY TRIAL OF THE HIGHEST RECOMMENDED DOSE OF SILDENAFIL IN PRETERM NEONATES (COHORT 3); WITH CLINICALLY RELEVANT OU
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N94018D00003 |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $1.5M |
| Current contract value | $1.5M |
| Potential contract value / ceiling | $1.5M |
| Start date | Jun 14, 2022 |
| Current end date | Feb 14, 2027 |
| Potential end date | Feb 14, 2027 |
| Latest award activity | Sep 9, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 9, 2025 | P00003 | $0 | NICHD: R&D: SAFETY OF SILDENAFIL IN PREMATURE INFANTS AT RISK OF BRONCHOPULMONARY DYSPLASIA (SILDENAFIL 2.0): NON-SEVERABLE |
| Apr 25, 2025 | P00002 | $0 | NICHD: R&D: THE GOAL OF THIS TASK ORDER IS TO PERFORM PHARMACOEPIDEMIOLOGY RESEARCH AND A PK, PHARMACODYNAMIC, PHARMACOGENOMIC, EFFICIENCY, AND SAFETY TRIAL OF THE HIGHEST RECOMMENDED DOSE OF SILDENAFIL IN PRETERM NEONATES (COHORT 3); WITH CLINIC |
| Sep 3, 2024 | P00001 | $0 | THE GOAL OF THIS TASK ORDER IS TO PERFORM PHARMACOEPIDEMIOLOGY RESEARCH AND A PK, PHARMACODYNAMIC, PHARMACOGENOMIC, EFFICIENCY, AND SAFETY TRIAL OF THE HIGHEST RECOMMENDED DOSE OF SILDENAFIL IN PRETERM NEONATES (COHORT 3); WITH CLINICALLY RELEVANT OU |
| Jun 14, 2022 | 0 | $1.5M | THE GOAL OF THIS TASK ORDER IS TO PERFORM PHARMACOEPIDEMIOLOGY RESEARCH AND A PK, PHARMACODYNAMIC, PHARMACOGENOMIC, EFFICIENCY, AND SAFETY TRIAL OF THE HIGHEST RECOMMENDED DOSE OF SILDENAFIL IN PRETERM NEONATES (COHORT 3); WITH CLINICALLY RELEVANT OU |
Estimated positioning window
Nov 1, 2026 – Jan 30, 2027
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2027-02-14 (105 days from calculation)
- +35 points
- 132 historical awards in this buyer and category group
- +15 points
- 4 recorded award transactions
- +10 points
- Latest award action: 2025-09-09
- +0 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.